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I.  General Information 
 
1H NMR data and 13C NMR data were collected on a VARIAN 500 MHz spectrometer at 
ambient temperature.  19F NMR data and 31P NMR data were collected on a VARIAN 300 MHz 
spectrometer at ambient temperature. 
Anhydrous THF, CH2Cl2, and toluene were purified and dried using a solvent-purification 
system that contained activated alumina.  The following reagents were purchased and used as 
received: NiCl2⋅glyme (Strem), ligand 1 (Aldrich), DMA (Aldrich; anhydrous), zinc powder 
(Alfa-Aesar; ~100 mesh, 99.9%), iodine (Alfa-Aesar; crystalline, 99.5%), NaBH4 (Oakwood), 
triphenyl phosphite (Aldrich), N-bromosuccinimide (Aldrich), N-iodosuccinimide (AK 
Scientific), oxalyl chloride (Aldrich), DMSO (Aldrich; ≥99.5%), Et3N (Aldrich), 
trifluoromethyltrimethylsilane (Oakwood), TBAF (Aldrich; 1.0 M in THF), triphenylphosphine 
(Oakwood), and tetrabromomethane (TCI).  NaBr (Aldrich; ≥99%; granular) was dried at 140 
°C for 12 h prior to use.  All alkyl bromides were purchased (Aldrich, Alfa Aesar, TCI, and 
Oakwood) and used as received. 
All reactions were carried out in oven-dried glassware under an inert atmosphere. 
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II.      Preparation  of  Electrophiles  
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General Procedure A: Synthesis of Electrophiles with a Perfluoroalkyl Group 
Preparation of the ketone using a Grignard reagent.  A solution of the Grignard reagent in 
THF (1.0 M, 40 mmol; 1.0 equiv) was added by syringe to a solution of the Weinreb amide1 (40 
mmol) in THF (20 mL) at 0 °C.  The reaction mixture was stirred at 0 °C for 15 min, and then it 
was allowed to warm to r.t. and stirred for 15 h.  Next, water was added to quench the reaction 
at 0 °C.  A solution of 1 N HCl (50 mL) was added, and then the mixture was extracted with 
CH2Cl2 (3 × 50 mL).  The organic layers were combined, dried over Na2SO4, and concentrated.  
The crude product was purified by flash chromatography on silica gel. 
Reduction of the ketone to the alcohol.  NaBH4 (2.3 g, 60 mmol; 3.0 equiv) was added in 
portions to a solution of the ketone (20 mmol) in Et2O (20 mL) and MeOH (20 mL) at 0 °C 
(CAUTION: very exothermic).  After the addition was complete, the mixture was stirred at 0 
°C for 30 min, and then it was allowed to warm to r.t. and stirred for 30 min.  Next, Et2O (30 
mL) was added to dilute the reaction mixture, the mixture was cooled to 0 °C, and then 
deionized water (30 mL) was added to quench the reaction.  The mixture was extracted with 
CH2Cl2 (3 × 50 mL), and the combined organic layers were dried over Na2SO4 and concentrated.  
The crude product was purified by flash chromatography on silica gel. 
Bromination  of  the  alcohol.2      Triphenylphosphite  (4.0  g,  3.4  mL;  1.3  equiv)  was  added  over  
5  min  to  a  solution  of  N-­‐‑bromosuccinimide  (2.3  g,  13  mmol;  1.3  equiv)  in  CH2Cl2  (10  mL)  at  0  °C  
(CAUTION: exothermic).      Next,  a  solution  of  the  alcohol  (10  mmol)  in  CH2Cl2  (12  mL)  was  
added  to  the  mixture  at  0  °C.      The  reaction  mixture  was  heated  to  40  °C  and  then  stirred  at  40  
°C  for  12  h.      Next,  the  solvent  was  evaporated,  and  the  product  was  purified  by  flash  
chromatography  on  silica  gel.  
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General Procedure B: Synthesis of Electrophiles with a CF3 Group 
Swern oxidation of the alcohol.  DMSO (2.9 mL, 40 mmol; 2.0 equiv) was added slowly to 
a solution of oxalyl chloride (2.0 mL, 24 mmol; 1.2 equiv) in CH2Cl2 (150 mL) at −78 °C.  The 
resulting mixture was allowed to stir at −78 °C for 30 min.  Next, a solution of the alcohol (20 
                                                
(1)   Prepared  from  the  corresponding  acid  anhydride,  acid  chloride,  or  ester,  based  on  
published  procedures:  (a)  Regan,  J.  et  al.  J.  Med.  Chem.  2006,  49,  7887–7896.      (b)  Bergeron,  
M.;  Johnson,  T.;  Paquin,  J.-­‐‑F.  Angew.  Chem.  Int.  Ed.  2011,  50,  11112–11116.  
(2)   Bose,  A.  K.;  Lal,  B.  Tetrahedron  Lett.  1973,  14,  3937–3940.  
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mmol) in CH2Cl2 (30 mL) was added over 5 min to the mixture.  The resulting mixture was 
stirred at −78 °C for 45 min, and then NEt3 (11 mL, 80 mmol; 4.0 equiv) was added in one 
portion.  The mixture was allowed to warm to r.t., and then it was stirred at r.t. for 2 h.  Next, 
an aqueous saturated solution of NH4Cl (30 mL) was added to quench the reaction.  The 
resulting mixture was extracted with CH2Cl2 (3 × 70 mL), and the combined organic layers were 
dried over Na2SO4 and concentrated.  The crude product was purified by flash 
chromatography on silica gel. 
Trifluoromethylation of the aldehyde.3  A solution of TBAF (1.0 M in THF; 0.20 mL, 0.20 
mmol; 0.013 equiv) was added over 3 min to a solution of the aldehyde (15 mmol) and 
trifluoromethyltrimethylsilane (2.7 mL, 18 mmol; 1.2 equiv) in THF (20 mL) at 0 °C (CAUTION: 
very exothermic).  The reaction mixture was allowed to warm to r.t., and it was stirred for 1 h.  
Next, an aqueous solution of 1 N HCl (30 mL) was added, and the mixture was allowed to stir at 
r.t. for another 2 h.  Then, the mixture was extracted with CH2Cl2 (3 × 50 mL), and the 
combined organic layers were dried over Na2SO4 and concentrated.  The crude product was 
purified by flash chromatography on silica gel. 
The bromination step is the same as in General Procedure A. 
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General Procedure C: Synthesis of Electrophiles with a CF3 Group 
The first two steps are the same as in General Procedure B. 
Bromination of the alcohol.4  Triphenylphosphine (4.2 g, 16 mmol; 2.0 equiv) and 
tetrabromomethane (5.3 g, 16 mmol; 2.0 equiv) were added to a solution of the alcohol (8.0 
mmol) in toluene (20 mL).  The resulting mixture was heated to 110 °C and stirred at 110 °C for 
3 h, at which time it had turned into a yellow suspension.  Then, CH2Cl2 (50 mL) was added to 
the reaction mixture until it became a clear solution.  The solvents were then evaporated, and 
the crude product was purified by flash chromatography on silica gel. 
 
                                                
(3)   Krishnamurti,  R.;  Bellew,  D.  R.;  Prakash,  G.  K.  S.  J.  Org.  Chem.  1991,  56,  984−989.  
(4)   Lin,  X.;  Zheng,  F.;  Qing,  F.-­‐‑L.  Organometallics  2012,  31,  1578–1582.  
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III.      Nickel-­‐‑Catalyzed  Alkyl–Alkyl  Cross-­‐‑Couplings  
 
General procedure for the preparation of alkylzinc solutions (0.50 M).5  In the air, zinc 
powder (589 mg, 9.00 mmol; 1.50 equiv) was added to an oven-dried 20-mL vial equipped with 
a stir bar.  The vial was heated at 80 °C under high vacuum for 30 min.  After back-filling with 
nitrogen, iodine chips (76 mg, 0.30 mmol; 0.050 equiv) were added to the vial.  Then, the vial 
was evacuated and back-filled with nitrogen (three cycles).  DMA (5 mL) was added to the 
mixture, and the mixture was stirred until the red color had faded.  Next, the alkyl bromide 
(6.0 mmol; 1.0 equiv) was added.  The reaction mixture was stirred at 80 °C for 12 h, and then 
the mixture was allowed to cool to r.t.  The gray solution was filtered under an inert 
atmosphere by injection through a syringe filter directly into a nitrogen-filled, 20-mL vial sealed 
with a PTFE septum cap.  The alkylzinc solution was titrated using I2 according to Knochel’s 
method6 (the concentration was ~0.9 M).  This solution was diluted into a 0.50 M solution by 
the addition of DMA. 
These solutions of organozinc bromides can be stored at r.t. under an inert atmosphere for 
several weeks without deterioration. 
General Procedure: Cross-­‐‑Coupling.  In the air, the electrophile (0.80 mmol) and NaBr (82 
mg, 0.80 mmol; 1.0 equiv) were added to an oven-dried 20-mL vial equipped with a stir bar.  
The vial was closed with a PTFE septum cap and then evacuated and back-filled with nitrogen 
(three cycles).  In the air, NiCl2⋅glyme (17.6 mg, 0.080 mmol) and ligand 1 (26.5 mg, 0.088 
mmol) were added to an oven-dried 4-mL vial equipped with a stir bar.  The vial was closed 
with a PTFE septum cap and then evacuated and back-filled with nitrogen (three cycles).  
DMA (2.0 mL) was added to the 4-mL vial, and the mixture was vigorously stirred at r.t. for 25 
min.  The resulting solution was transferred via syringe to the 20-mL reaction vial that 
contained the electrophile.  The 4-mL vial was rinsed with DMA three times (0.7 mL, 0.7 mL, 
and 0.6 mL), and the washings were transferred to the 20-mL reaction vial.  The resulting 
solution was allowed to stir at r.t. for 1 min.  Then, the reaction vial was wrapped with 
electrical tape, and the alkylzinc solution (0.50 M; 1.9 mL, 0.95 mmol; 1.2 equiv) was added over 
1 min.  The mixture was stirred vigorously at r.t. for 5 h.  Then, the reaction was quenched by 
the addition of MeOH (0.5 mL).  The resulting mixture was allowed to stir for 1 min, and then 
it was diluted with Et2O (100 mL) and washed with deionized water (20 mL × 4).  The organic 
layer was dried over Na2SO4 and then concentrated, and the residue was purified by flash 
chromatography. 
 
 
                                                
(5)   (a)  Huo,  S.  Org.  Lett.  2003,  5,  423–425.      (b)  Son,  S.;  Fu,  G.  C.  J.  Am.  Chem.  Soc.  2008,  130,  
2756–2757.  
(6)   Krasovskiy,  A.;  Knochel,  P.  Synthesis  2006,  890−891.  
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((5,5,6,6,6-Pentafluoro-4-phenethylhexyl)oxy)benzene (Table 2, Entry 1).  The title 
compound was prepared according to the General Procedure with (3-bromo-4,4,5,5,5-
pentafluoropentyl)benzene (254 mg, 0.80 mmol) and an alkylzinc bromide reagent prepared 
from (3-bromopropoxy)benzene.  Solvent system for chromatography: 10:1 → 3:1 
hexane/dichloromethane.  The title compound was isolated as a colorless oil. 
Run 1, 217 mg (73% yield); Run 2, 220 mg (74% yield). 
1H NMR (500 MHz, CDCl3) δ 7.33 – 7.29 (m, 4H), 7.25 – 7.17 (m, 3H), 6.99 – 6.95 (m, 1H), 6.93 
– 6.89 (m, 2H), 3.96 (t, 2H, J = 5.8 Hz), 2.81 – 2.67 (m, 2H), 2.30 – 2.17 (m, 1H), 2.13 – 2.02 (m, 1H), 
1.98 – 1.69 (m, 5H); 
13C NMR (126 MHz, CDCl3) δ 158.8, 141.0, 129.5, 128.6, 128.3, 126.2, 121.0 – 115.1 (m), 120.8, 
114.4, 67.1, 39.6 (t, J = 19.9 Hz), 32.9, 28.5, 26.3, 23.4; 
19F NMR (282 MHz, CDCl3) δ −81.7 (s, 3F), −117.0 (d, 2F, J = 16.1 Hz); 
FT-IR (film) 2960, 1601, 1587, 1497, 1472, 1246, 1203, 1171, 754, 700, 692 cm-1; 
GC-MS (EI) m/z (M+) calcd for C20H21F5O: 372, found: 372. 
 
 
PhF3CF2C
O
 
4-(3,3,4,4,4-Pentafluoro-2-phenethylbutyl)tetrahydro-2H-pyran (Table 2, Entry 2).  The 
title compound was prepared according to the General Procedure with (3-bromo-4,4,5,5,5-
pentafluoropentyl)benzene (254 mg, 0.80 mmol) and an alkylzinc bromide reagent prepared 
from 4-(bromomethyl)tetrahydro-2H-pyran.  Solvent system for chromatography: 15:1 → 12:1 
hexane/ethyl acetate.  The title compound was isolated as a colorless oil. 
Run 1, 147 mg (55% yield); Run 2, 144 mg (54% yield). 
1H NMR (500 MHz, CDCl3) δ 7.34 – 7.28 (m, 2H), 7.24 – 7.16 (m, 3H), 3.96 – 3.87 (m, 2H), 3.38 
– 3.30 (m, 1H), 3.28 – 3.19 (m, 1H), 2.76 – 2.64 (m, 2H), 2.26 – 2.14 (m, 1H), 2.11 – 2.00 (m, 1H), 
1.76 – 1.66 (m, 1H), 1.64 – 1.43 (m, 3H), 1.42 – 1.23 (m, 3H), 1.20 – 1.09 (m, 1H); 
13C NMR (126 MHz, CDCl3) δ 141.0, 128.6, 128.4, 126.3, 121.6 – 114.0 (m), 67.8, 67.7, 36.5 (t, J = 
19.9 Hz), 34.5, 33.5, 33.2, 32.5, 32.3, 29.7; 
19F NMR (282 MHz, CDCl3) δ −81.4 (s, 3F), −116.2 – −118.3 (m, 2F); 
FT-IR (film) 2934, 2843, 1455, 1201, 1108, 700 cm-1; 
GC-MS (EI) m/z (M+) calcd for C17H21F5O: 336, found: 336. 
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2-(4,4,5,5,5-Pentafluoro-3-phenethylpentyl)-1,3-dioxolane (Table 2, Entry 3).  The title 
compound was prepared according to the General Procedure with (3-bromo-4,4,5,5,5-
pentafluoropentyl)benzene (254 mg, 0.80 mmol) and an alkylzinc bromide reagent prepared 
from 2-(2-bromoethyl)-1,3-dioxolane.  Solvent system for chromatography: 10:1 → 4:1 
hexane/ethyl acetate.  The title compound was isolated as a colorless oil. 
Run 1, 166 mg (61% yield); Run 2, 161 mg (60% yield). 
1H NMR (500 MHz, CDCl3) δ 7.33 – 7.28 (m, 2H), 7.24 – 7.17 (m, 3H), 4.86 (t, 1H, J = 4.3 Hz), 
4.02 – 3.94 (m, 2H), 3.91 – 3.83 (m, 2H), 2.75 (ddd, 1H, J = 13.8, 10.6, 5.7 Hz), 2.67 (ddd, 1H, J = 
13.7, 10.4, 6.2 Hz), 2.29 – 2.16 (m, 1H), 2.02 (ddt, 1H, J = 19.6, 10.8, 5.1 Hz), 1.92 – 1.62 (m, 5H); 
13C NMR (126 MHz, CDCl3) δ 141.1, 128.5, 128.3, 126.2, 121.2 – 116.1 (m), 103.9, 64.97, 64.94, 
39.6 (t, J = 19.9 Hz), 32.8, 30.6, 28.5, 20.7; 
19F NMR (282 MHz, CDCl3) δ −81.7 (s, 3F), −117.1 (d, 2F, J = 16.1 Hz); 
FT-IR (film) 2958, 2885, 1203, 1143, 1096, 1008, 700 cm-1; 
GC-MS (EI) m/z (M+) calcd for C16H19F5O2: 338, found: 338. 
 
 
PhF3CF2C
Ph
 
(6-(Perfluoroethyl)oct-1-yne-1,8-diyl)dibenzene (Table 2, Entry 4).  The title compound 
was prepared according to the General Procedure with (3-bromo-4,4,5,5,5-
pentafluoropentyl)benzene (254 mg, 0.80 mmol) and an alkylzinc bromide reagent prepared 
from (5-bromopent-1-yn-1-yl)benzene.  Solvent system for chromatography: 20:1 → 15:1 
hexane/dichloromethane.  The title compound was isolated as a colorless oil. 
Run 1, 173 mg (57% yield); Run 2, 183 mg (60% yield). 
1H NMR (500 MHz, CDCl3) δ 7.43 – 7.38 (m, 2H), 7.33 – 7.28 (m, 5H), 7.25 – 7.18 (m, 3H), 2.82 
– 2.67 (m, 2H), 2.44 (t, 2H, J = 6.6 Hz), 2.27 – 2.14 (m, 1H), 2.06 (dddd, 1H, J = 14.8, 10.7, 6.4, 4.4 
Hz), 1.93 (ddt, 1H, J = 13.0, 8.2, 4.1 Hz), 1.86 – 1.62 (m, 4H); 
13C NMR (126 MHz, CDCl3) δ 141.0, 131.5, 128.5, 128.3, 128.2, 127.7, 126.2, 123.7, 121.5 – 115.0 
(m), 89.1, 81.4, 39.5 (t, J = 20.0 Hz), 32.9, 28.5, 25.9, 25.7, 19.4; 
19F NMR (282 MHz, CDCl3) δ −81.7 (s, 3F), −117.0 (d, 2F, J = 16.2 Hz); 
FT-IR (film) 3028, 2959, 1490, 1454, 1202, 1171, 1122, 1094, 1008, 756, 692 cm-1; 
GC-MS (EI) m/z (M+) calcd for C22H21F5: 380, found: 380. 
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Ethyl 6,6,7,7,7-pentafluoro-5-phenethylheptanoate (Table 2, Entry 5).  The title compound 
was prepared according to the General Procedure with (3-bromo-4,4,5,5,5-
pentafluoropentyl)benzene (254 mg, 0.80 mmol) and an alkylzinc bromide reagent prepared 
from ethyl 4-bromobutanoate.  Solvent system for chromatography: 2:1 → 1:1.5 
hexane/dichloromethane.  The title compound was isolated as a colorless oil. 
Run 1, 192 mg (68% yield); Run 2, 180 mg (64% yield). 
1H NMR (500 MHz, CDCl3) δ 7.33 – 7.28 (m, 2H), 7.24 – 7.17 (m, 3H), 4.15 (q, 2H, J = 7.1 Hz), 
2.78 – 2.64 (m, 2H), 2.31 (t, 2H, J = 6.8 Hz), 2.21 – 2.08 (m, 1H), 2.06 – 1.99 (m, 1H), 1.85 – 1.51 (m, 
5H), 1.27 (t, 3H, J = 7.1 Hz); 
13C NMR (126 MHz, CDCl3) δ 173.0, 141.0, 128.5, 128.3, 126.2, 121.1 – 114.8 (m), 60.4, 39.7 (t, J 
= 20.0 Hz), 34.1, 32.9, 28.5, 26.2, 22.0, 14.2; 
19F NMR (282 MHz, CDCl3) δ −81.7 (s, 3F), −117.1 (d, 2F, J = 16.2 Hz); 
FT-IR (film) 2963, 1735, 1201, 1123, 1095, 1007, 753, 700 cm-1; 
GC-MS (EI) m/z (M+) calcd for C17H21F5O2: 352, found: 352. 
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Diethyl (5,5,6,6,6-pentafluoro-4-phenethylhexyl)phosphonate (Table 2, Entry 6).  The title 
compound was prepared according to the General Procedure with (3-bromo-4,4,5,5,5-
pentafluoropentyl)benzene (254 mg, 0.80 mmol) and an alkylzinc bromide reagent prepared 
from diethyl (3-bromopropyl)phosphonate.  Solvent system for chromatography: 1:1 → 1:2.5 
hexane/ethyl acetate.  The title compound was isolated as a colorless oil. 
Run 1, 237 mg (71% yield); Run 2, 230 mg (69% yield). 
1H NMR (500 MHz, CDCl3) δ 7.32 – 7.27 (m, 2H), 7.23 – 7.15 (m, 3H), 4.16 – 4.03 (m, 4H), 2.75 
– 2.63 (m, 2H), 2.17 – 2.07 (m, 1H), 2.05 – 1.96 (m, 1H), 1.84 – 1.56 (m, 7H), 1.32 (t, 6H, J = 7.1 Hz); 
13C NMR (126 MHz, CDCl3) δ 140.9, 128.5, 128.3, 126.2, 121.2 – 114.7 (m), 61.6 (d, J = 6.6 Hz), 
39.7 (t, J = 20.0 Hz), 32.9, 28.5, 27.6 (d, J = 16.7 Hz), 25.7 (d, J = 141.8 Hz), 20.0 (d, J = 4.9 Hz), 16.4 
(d, J = 6.0 Hz); 
19F NMR (282 MHz, CDCl3) δ −81.7 (s, 3F), −116.9 (t, 2F, J = 16.9 Hz); 
31P NMR (121 MHz, CDCl3) δ 31.2; 
FT-IR (film) 2981, 1244, 1203, 1169, 1058, 1031, 960, 701 cm-1; 
GC-MS (EI) m/z (M+) calcd for C18H26F5O3P: 416, found: 416. 
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6,6,7,7,7-Pentafluoro-5-phenethylheptanenitrile (Table 2, Entry 7).  The title compound 
was prepared according to the General Procedure with (3-bromo-4,4,5,5,5-
pentafluoropentyl)benzene (254 mg, 0.80 mmol) and an alkylzinc bromide reagent prepared 
from 4-bromobutanenitrile.  Solvent system for chromatography: 10:1 → 3:1 hexane/ethyl 
acetate.  The title compound was isolated as a yellow oil. 
Run 1, 190 mg (78% yield); Run 2, 183 mg (75% yield). 
1H NMR (500 MHz, CDCl3) δ 7.34 – 7.30 (m, 2H), 7.25 – 7.21 (m, 1H), 7.20 – 7.17 (m, 2H), 2.80 
– 2.64 (m, 2H), 2.35 – 2.29 (m, 2H), 2.22 – 2.02 (m, 2H), 1.90 – 1.64 (m, 5H); 
13C NMR (126 MHz, CDCl3) δ 140.4, 128.6, 128.3, 126.4, 120.5 – 114.8 (m), 118.9, 39.3 (t, J = 
20.1 Hz), 32.8, 28.3, 26.0, 22.6, 17.3; 
19F NMR (282 MHz, CDCl3) δ −81.7 (s, 3F), −116.3 (dd, 1F, J = 274.0, 15.2 Hz), −117.6 (dd, 1F, J 
= 273.9, 16.4 Hz); 
FT-IR (film) 2952, 2247, 1497, 1455, 1335, 1203, 1173, 1124, 1096, 1007, 753, 701 cm-1; 
GC-MS (EI) m/z (M+) calcd for C15H16F5N: 305, found: 305. 
 
 
F3CF2C
Cl
OPh
 
((9-Chloro-4-(perfluoroethyl)nonyl)oxy)benzene (Table 2, Entry 8).  The title compound 
was prepared according to the General Procedure with 3-bromo-8-chloro-1,1,1,2,2-
pentafluorooctane (254 mg, 0.80 mmol) and an alkylzinc bromide reagent prepared from (3-
bromopropoxy)benzene.  Solvent system for chromatography: 10:1 → 8:1 
hexane/dichloromethane.  The title compound was isolated as a colorless oil. 
Run 1, 188 mg (63% yield); Run 2, 192 mg (64% yield). 
1H NMR (500 MHz, CDCl3) δ 7.32 – 7.27 (m, 2H), 6.97 – 6.94 (m, 1H), 6.92 – 6.88 (m, 2H), 4.01 
– 3.94 (m, 2H), 3.53 (t, 2H, J = 6.6 Hz), 2.23 – 2.12 (m, 1H), 1.95 – 1.62 (m, 7H), 1.56 – 1.33 (m, 5H); 
13C NMR (126 MHz, CDCl3) δ 158.8, 129.5, 120.8, 119.6 – 115.9 (m), 114.4, 67.2, 44.9, 40.2 (t, J = 
19.8 Hz), 32.3, 26.9, 26.6, 26.5, 26.1, 23.4; 
19F NMR (282 MHz, CDCl3) δ −81.7 (s, 3F), −117.2 (dd, 2F, J = 16.2, 13.2 Hz); 
FT-IR (film) 2954, 2871, 1601, 1587, 1498, 1471, 1246, 1202, 1018, 755, 692 cm-1; 
GC-MS (EI) m/z (M+) calcd for C17H22ClF5O: 372, found: 372. 
 
 
n-C3F7 Ph
OPh
 
(4,4,5,5,6,6,6-Heptafluoro-3-(3-phenoxypropyl)hexyl)benzene (Table 3, Entry 1).  The title 
compound was prepared according to the General Procedure with (3-bromo-4,4,5,5,6,6,6-
heptafluorohexyl)benzene (294 mg, 0.80 mmol) and an alkylzinc bromide reagent prepared 
 S–9 
from (3-bromopropoxy)benzene.  Solvent system for chromatography: 10:1 → 3:1 
hexane/dichloromethane.  The title compound was isolated as a colorless oil. 
Run 1, 220 mg (65% yield); Run 2, 220 mg (65% yield). 
1H NMR (500 MHz, CDCl3) δ 7.33 – 7.28 (m, 4H), 7.25 – 7.17 (m, 3H), 6.99 – 6.95 (m, 1H), 6.93 
– 6.89 (m, 2H), 3.99 – 3.94 (m, 2H), 2.79 (ddd, 1H, J = 13.8, 10.4, 5.7 Hz), 2.70 (ddd, 1H, J = 13.7, 
10.2, 6.2 Hz), 2.39 – 2.24 (m, 1H), 2.14 – 2.04 (m, 1H), 2.00 – 1.72 (m, 5H); 
13C NMR (126 MHz, CDCl3) δ 158.8, 141.0, 129.5, 128.6, 128.4, 126.2, 121.1 – 109.7 (m), 120.8, 
114.4, 67.2, 39.9 (t, J = 20.1 Hz), 32.9, 28.5, 26.3, 23.3; 
19F NMR (282 MHz, CDCl3) δ −80.7 (t, 3F, J = 11.0 Hz), −114.1 – −114.4 (m, 2F), −124.6 – 
−124.8 (m, 2F); 
FT-IR (film) 3029, 2952, 1601, 1498, 1226, 1173, 1111, 753, 699, 692 cm-1; 
GC-MS (EI) m/z (M+) calcd for C21H21F7O: 422, found: 422. 
 
 
n-C3F7 Ph
O
OEt
 
Ethyl 6,6,7,7,8,8,8-heptafluoro-5-phenethyloctanoate (Table 3, Entry 2).  The title 
compound was prepared according to the General Procedure with (3-bromo-4,4,5,5,6,6,6-
heptafluorohexyl)benzene (294 mg, 0.80 mmol) and an alkylzinc bromide reagent prepared 
from ethyl 4-bromobutanoate.  Solvent system for chromatography: 2:1 → 1:1.5 
hexane/dichloromethane.  The title compound was isolated as a colorless oil. 
Run 1, 174 mg (54% yield); Run 2, 174 mg (54% yield). 
1H NMR (500 MHz, CDCl3) δ 7.33 – 7.28 (m, 2H), 7.24 – 7.17 (m, 3H), 4.15 (q, 2H, J = 7.1 Hz), 
2.79 – 2.64 (m, 2H), 2.31 (t, 2H, J = 6.7 Hz), 2.28 – 2.18 (m, 1H), 2.09 – 2.00 (m, 1H), 1.86 – 1.53 (m, 
5H), 1.27 (t, 3H, J = 7.1 Hz); 
13C NMR (126 MHz, CDCl3) δ 173.0, 141.0, 128.5, 128.3, 126.2, 121.9 – 107.1 (m), 60.4, 40.1 (t, J 
= 20.0 Hz), 34.1, 32.9, 28.5, 26.1, 22.0, 14.2; 
19F NMR (282 MHz, CDCl3) δ −80.8 (t, 3F, J = 11.0 Hz), −114.1 – −114.4 (m, 2F), −124.7 – 
−124.8 (m, 2F); 
FT-IR (film) 2963, 1736, 1225, 1178, 1107, 748, 700 cm-1; 
GC-MS (EI) m/z (M+) calcd for C18H21F7O2: 402, found: 402. 
 
 
n-C3F7 Ph
P
OEt
O
OEt
 
Diethyl (5,5,6,6,7,7,7-heptafluoro-4-phenethylheptyl)phosphonate (Table 3, Entry 3).  The 
title compound was prepared according to the General Procedure with (3-bromo-4,4,5,5,6,6,6-
heptafluorohexyl)benzene (294 mg, 0.80 mmol) and an alkylzinc bromide reagent prepared 
from diethyl (3-bromopropyl)phosphonate.  Solvent system for chromatography: 1:1 → 1:2.5 
hexane/ethyl acetate.  The title compound was isolated as a colorless oil. 
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Run 1, 186 mg (50% yield); Run 2, 190 mg (51% yield). 
1H NMR (500 MHz, CDCl3) δ 7.32 – 7.27 (m, 2H), 7.23 – 7.15 (m, 3H), 4.16 – 4.03 (m, 4H), 2.77 
– 2.62 (m, 2H), 2.28 – 2.14 (m, 1H), 2.08 – 1.98 (m, 1H), 1.88 – 1.59 (m, 7H), 1.32 (t, 6H, J = 7.1 Hz); 
13C NMR (126 MHz, CDCl3) δ 140.9, 128.5, 128.3, 126.2, 121.7 – 107.0 (m), 61.6 (d, J = 6.5 Hz), 
40.1 (t, J = 20.0 Hz), 32.9, 28.5, 27.6 (d, J = 17.0 Hz), 25.7 (d, J = 141.8 Hz), 19.9 (d, J = 4.8 Hz), 16.4 
(d, J = 6.0 Hz); 
19F NMR (282 MHz, CDCl3) δ −80.8 (t, 3F, J = 11.0 Hz), −114.0 – −114.3 (m, 2F), −124.6 – 
−124.8 (m, 2F); 
31P NMR (121 MHz, CDCl3) δ 31.2; 
FT-IR (film) 2981, 1349, 1231, 1176, 1103, 1059, 1031, 958, 749, 701 cm-1; 
GC-MS (EI) m/z (M+) calcd for C19H26F7O3P: 466, found: 466. 
 
 
n-C3F7 Ph
CN
 
6,6,7,7,8,8,8-Heptafluoro-5-phenethyloctanenitrile (Table 3, Entry 4).  The title compound 
was prepared according to the General Procedure with (3-bromo-4,4,5,5,6,6,6-
heptafluorohexyl)benzene (294 mg, 0.80 mmol) and an alkylzinc bromide reagent prepared 
from 4-bromobutanenitrile.  Solvent system for chromatography: 10:1 → 4:1 hexane/ethyl 
acetate.  The title compound was isolated as a colorless oil. 
Run 1, 200 mg (70% yield); Run 2, 190 mg (67% yield). 
1H NMR (500 MHz, CDCl3) δ 7.35 – 7.29 (m, 2H), 7.27 – 7.16 (m, 3H), 2.81 – 2.65 (m, 2H), 2.37 
– 2.18 (m, 3H), 2.13 – 2.06 (m, 1H), 1.92 – 1.66 (m, 5H); 
13C NMR (126 MHz, CDCl3) δ 140.4, 128.6, 128.3, 126.4, 121.7 – 107.5 (m), 118.9, 39.6 (t, J = 
20.3 Hz), 32.9, 28.3, 26.0, 22.6, 17.3; 
19F NMR (282 MHz, CDCl3) δ −80.7 (t, 3F, J = 11.0 Hz), −114.0 – −114.4 (m, 2F), −124.6 – 
−124.9 (m, 2F); 
FT-IR (film) 2952, 2247, 1497, 1455, 1350, 1225, 1176, 1108, 748, 701 cm-1; 
GC-MS (EI) m/z (M+) calcd for C16H16F7N: 355, found: 355. 
 
 
n-C4F9 Ph
OPh
 
(4,4,5,5,6,6,7,7,7-Nonafluoro-3-(3-phenoxypropyl)heptyl)benzene (Table 3, Entry 5).  The 
title compound was prepared according to the General Procedure with (3-bromo-
4,4,5,5,6,6,7,7,7-nonafluoroheptyl)benzene (334 mg, 0.80 mmol) and an alkylzinc bromide 
reagent prepared from (3-bromopropoxy)benzene.  Solvent system for chromatography: 
hexane → 4:1 hexane/dichloromethane.  The title compound was isolated as a colorless oil. 
Run 1, 255 mg (67% yield); Run 2, 250 mg (66% yield). 
1H NMR (500 MHz, CDCl3) δ 7.34 – 7.28 (m, 4H), 7.25 – 7.17 (m, 3H), 6.99 – 6.95 (m, 1H), 6.93 
– 6.89 (m, 2H), 4.00 – 3.94 (m, 2H), 2.81 – 2.67 (m, 2H), 2.39 – 2.28 (m, 1H), 2.14 – 2.04 (m, 1H), 
2.01 – 1.71 (m, 5H); 
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13C NMR (126 MHz, CDCl3) δ 158.8, 141.0, 129.5, 128.6, 128.3, 126.2, 121.9 – 116.0 (m), 120.8, 
114.4, 67.2, 40.1 (t, J = 20.2 Hz), 32.9, 28.5, 26.3, 23.3; 
19F NMR (282 MHz, CDCl3) δ −80.8 – −81.0 (m, 3F), −113.5 – −113.8 (m, 2F), −121.3 – −121.6  
(m, 2F), −126.0 – −126.2 (m, 2F); 
FT-IR (film) 3029, 2952, 1601, 1498, 1236, 1172, 1133, 752, 699, 692 cm-1; 
GC-MS (EI) m/z (M+) calcd for C22H21F9O: 472, found: 472. 
 
 
n-C4F9 Ph
O
OEt
 
Ethyl 6,6,7,7,8,8,9,9,9-nonafluoro-5-phenethylnonanoate (Table 3, Entry 6).  The title 
compound was prepared according to the General Procedure with (3-bromo-4,4,5,5,6,6,7,7,7-
nonafluoroheptyl)benzene (334 mg, 0.80 mmol) and an alkylzinc bromide reagent prepared 
from ethyl 4-bromobutanoate.  Solvent system for chromatography: hexane → 1:1.5 
hexane/dichloromethane.  The title compound was isolated as a colorless oil. 
Run 1, 200 mg (55% yield); Run 2, 188 mg (52% yield). 
1H NMR (500 MHz, CDCl3) δ 7.33 – 7.28 (m, 2H), 7.24 – 7.17 (m, 3H), 4.15 (q, 2H, J = 7.2 Hz), 
2.78 – 2.65 (m, 2H), 2.34 – 2.18 (m, 3H), 2.10 – 2.00 (m, 1H), 1.86 – 1.54 (m, 5H), 1.27 (t, 3H, J = 7.1 
Hz); 
13C NMR (126 MHz, CDCl3) δ 173.0, 141.0, 128.5, 128.3, 126.2, 121.8 – 115.4 (m), 60.4, 40.3 (t, J 
= 20.2 Hz), 34.1, 32.9, 28.5, 26.1, 22.0, 14.2; 
19F NMR (282 MHz, CDCl3) δ −80.8 – −81.0 (m, 3F), −113.6 – −113.9 (m, 2F), −121.4 – −121.6  
(m, 2F), −126.0 – −126.3 (m, 2F); 
FT-IR (film) 2963, 1735, 1235, 1133, 750, 700 cm-1; 
GC-MS (EI) m/z (M+) calcd for C19H21F9O2: 452, found: 452. 
 
 
n-C4F9 Ph
CN
 
6,6,7,7,8,8,9,9,9-Nonafluoro-5-phenethylnonanenitrile (Table 3, Entry 7).  The title 
compound was prepared according to the General Procedure with (3-bromo-4,4,5,5,6,6,7,7,7-
nonafluoroheptyl)benzene (334 mg, 0.80 mmol) and an alkylzinc bromide reagent prepared 
from 4-bromobutanenitrile.  Solvent system for chromatography: hexane → 4:1 hexane/ethyl 
acetate.  The title compound was isolated as a colorless oil. 
Run 1, 221 mg (68% yield); Run 2, 227 mg (70% yield). 
1H NMR (500 MHz, CDCl3) δ 7.35 – 7.30 (m, 2H), 7.26 – 7.21 (m, 1H), 7.21 – 7.17 (m, 2H), 2.80 
– 2.65 (m, 2H), 2.37 – 2.21 (m, 3H), 2.15 – 2.05 (m, 1H), 1.92 – 1.66 (m, 5H); 
13C NMR (126 MHz, CDCl3) δ 140.4, 128.7, 128.3, 126.4, 121.6 – 116.0 (m), 118.9, 39.8 (t, J = 
20.3 Hz), 32.9, 28.3, 26.0, 22.6, 17.3; 
19F NMR (282 MHz, CDCl3) δ −80.8 – −81.0 (m, 3F), −113.4 – −113.8 (m, 2F), −121.3 – −121.6  
(m, 2F), −126.0 – −126.2 (m, 2F); 
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FT-IR (film) 2952, 2247, 1354, 1235, 1133, 1019, 750, 701 cm-1; 
GC-MS (EI) m/z (M+) calcd for C17H16F9N: 405, found: 405. 
 
 
n-C9F19 Ph
CN
 
6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,14-Nonadecafluoro-5-
phenethyltetradecanenitrile (Table 3, Entry 8).  The title compound was prepared according 
to the General Procedure with (3-bromo-4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,12-
nonadecafluorododecyl)benzene (534 mg, 0.80 mmol) and an alkylzinc bromide reagent 
prepared from 4-bromobutanenitrile.  Solvent system for chromatography: hexane → 4:1 
hexane/ethyl acetate.  The title compound was isolated as a colorless viscous oil. 
Run 1, 340 mg (65% yield); Run 2, 351 mg (67% yield). 
1H NMR (500 MHz, CDCl3) δ 7.35 – 7.29 (m, 2H), 7.25 – 7.17 (m, 3H), 2.81 – 2.65 (m, 2H), 2.37 
– 2.21 (m, 3H), 2.14 – 2.06 (m, 1H), 1.92 – 1.66 (m, 5H); 
13C NMR (126 MHz, CDCl3) δ 140.5, 128.7, 128.3, 126.4, 120.2 – 105.1 (m), 118.9, 40.0 (t, J = 
20.2 Hz), 32.9, 28.4, 26.0, 22.6, 17.3; 
19F NMR (282 MHz, CDCl3) δ −80.8 (t, 3F, J = 10.0 Hz), −113.2 – −113.6 (m, 2F), −120.3 – 
−120.7 (m, 2F), −121.5 – −122.2 (m, 8F), −122.6 – −123.0 (m, 2F), −126.0 – 126.4 (m, 2F); 
FT-IR (film) 2954, 2247, 1497, 1455, 1209, 1100, 739, 702, 658 cm-1; 
GC-MS (EI) m/z (M+−C9F19) calcd for C13H16N: 186, found: 186. 
 
 
PhF3C
n-Bu
 
(3-(Trifluoromethyl)dodecyl)benzene (Table 4, Entry 1).  The title compound was 
prepared according to the General Procedure with (3-bromo-4,4,4-trifluorobutyl)benzene (214 
mg, 0.80 mmol) and an alkylzinc bromide reagent prepared from 1-bromononane.  Solvent 
system for chromatography: hexane.  The title compound was isolated as a colorless oil. 
Run 1, 199 mg (79% yield); Run 2, 197 mg (78% yield). 
1H NMR (500 MHz, CDCl3) δ 7.34 – 7.28 (m, 2H), 7.24 – 7.18 (m, 3H), 2.71 (t, 2H, J = 8.2 Hz), 
2.12 – 2.01 (m, 1H), 1.99 – 1.89 (m, 1H), 1.80 – 1.71 (m, 1H), 1.68 – 1.59 (m, 1H), 1.52 – 1.22 (m, 
15H), 0.90 (t, 3H, J = 6.9 Hz); 
13C NMR (126 MHz, CDCl3) δ 141.4, 128.7 (q, J = 280.4 Hz), 128.5, 128.4, 126.1, 41.9 (q, J = 24.8 
Hz), 33.1, 31.9, 29.64, 29.61, 29.5, 29.4, 29.3, 27.8 (q, J = 2.3 Hz), 26.7, 22.7, 14.1; 
19F NMR (282 MHz, CDCl3) δ −69.9 (d, 3F, J = 9.5 Hz); 
FT-IR (film) 2926, 2855, 1455, 1260, 1153, 1129, 1104, 746, 699 cm-1; 
GC-MS (EI) m/z (M+) calcd for C19H29F3: 314, found: 314. 
 
 
 S–13 
F3C Ph
Ph
 
(3-(Trifluoromethyl)pentane-1,5-diyl)dibenzene (Table 4, Entry 2).  The title compound 
was prepared according to the General Procedure with (3-bromo-4,4,4-trifluorobutyl)benzene 
(214 mg, 0.80 mmol) and an alkylzinc bromide reagent prepared from (2-bromoethyl)benzene.  
Solvent system for chromatography: hexane.  The title compound was isolated as a colorless 
oil. 
Run 1, 182 mg (78% yield); Run 2, 182 mg (78% yield). 
1H NMR (500 MHz, CDCl3) δ 7.34 – 7.29 (m, 4H), 7.26 – 7.21 (m, 2H), 7.19 – 7.15 (m, 4H), 2.77 
– 2.65 (m, 4H), 2.19 – 2.08 (m, 1H), 2.00 (dddd, 2H, J = 14.8, 9.2, 6.8, 5.7 Hz), 1.82 (ddt, 2H, J = 
13.7, 9.4, 6.7 Hz); 
13C NMR (126 MHz, CDCl3) δ 141.1, 128.58 (q, J = 281.1 Hz), 128.53, 128.4, 126.2, 41.2 (q, J = 
25.0 Hz), 32.9, 29.7 (d, J = 2.4 Hz); 
19F NMR (282 MHz, CDCl3) δ −69.7 (d, 3F, J = 9.4 Hz); 
FT-IR (film) 3027, 2937, 1497, 1454, 1260, 1145, 1113, 747, 699 cm-1; 
GC-MS (EI) m/z (M+) calcd for C18H19F3: 292, found: 292. 
 
 
F3C Ph
OPh
 
(6-Phenoxy-3-(trifluoromethyl)hexyl)benzene (Table 4, Entry 3).  The title compound was 
prepared according to the General Procedure with (3-bromo-4,4,4-trifluorobutyl)benzene (214 
mg, 0.80 mmol) and an alkylzinc bromide reagent prepared from (3-bromopropoxy)benzene.  
Solvent system for chromatography: 6:1 → 5:1 hexane/dichloromethane.  The title compound 
was isolated as a colorless oil. 
Run 1, 213 mg (83% yield); Run 2, 213 mg (83% yield). 
1H NMR (500 MHz, CDCl3) δ 7.34 – 7.28 (m, 4H), 7.25 – 7.18 (m, 3H), 6.99 – 6.96 (m, 1H), 6.93 
– 6.89 (m, 2H), 3.96 (t, 2H, J = 5.9 Hz), 2.81 – 2.69 (m, 2H), 2.21 – 2.13 (m, 1H), 2.01 (dddd, 1H, J = 
14.2, 9.4, 6.7, 5.6 Hz), 1.93 – 1.69 (m, 5H); 
13C NMR (126 MHz, CDCl3) δ 158.8, 141.1, 129.5, 128.54 (q, J = 280.3 Hz), 128.52, 128.4, 126.2, 
120.7, 114.4, 67.2, 41.6 (q, J = 25.1 Hz), 32.9, 29.5 (q, J = 2.4 Hz), 26.4, 24.4 (q, J = 2.5 Hz); 
19F NMR (282 MHz, CDCl3) δ −69.8 (d, 3F, J = 9.4 Hz); 
FT-IR (film) 2953, 2874, 1601, 1497, 1246, 1152, 1120, 754, 700, 692 cm-1; 
GC-MS (EI) m/z (M+) calcd for C19H21F3O: 322, found: 322. 
 
 
PhF3C
O
 
4-(4-Phenyl-2-(trifluoromethyl)butyl)tetrahydro-2H-pyran (Table 4, Entry 4).  The title 
compound was prepared according to the General Procedure with (3-bromo-4,4,4-
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trifluorobutyl)benzene (214 mg, 0.80 mmol) and an alkylzinc bromide reagent prepared from 4-
(bromomethyl)tetrahydro-2H-pyran.  Solvent system for chromatography: 12:1 hexane/ethyl 
acetate.  The title compound was isolated as a colorless oil. 
Run 1, 167 mg (73% yield); Run 2, 169 mg (74% yield). 
1H NMR (500 MHz, CDCl3) δ 7.33 – 7.28 (m, 2H), 7.24 – 7.17 (m, 3H), 3.97 – 3.87 (m, 2H), 3.35 
(td, 1H, J = 11.8, 2.1 Hz), 3.27 (td, 1H, J = 11.8, 2.3 Hz), 2.78 – 2.65 (m, 2H), 2.19 – 2.09 (m, 1H), 
1.98 (ddt, 1H, J = 14.3, 9.2, 6.2 Hz), 1.74 – 1.66 (m, 1H), 1.59 – 1.51 (m, 3H), 1.40 – 1.12 (m, 4H); 
13C NMR (126 MHz, CDCl3) δ 141.0, 128.6 (q, J = 280.2 Hz), 128.5, 128.4, 126.2, 67.82, 67.76, 
38.4 (q, J = 25.0 Hz), 35.4 (q, J = 2.3 Hz), 33.2, 33.0, 32.7, 32.3, 30.2 (q, J = 2.3 Hz); 
19F NMR (282 MHz, CDCl3) δ −70.3 (d, 3F, J = 9.2 Hz); 
FT-IR (film) 2935, 2842, 1261, 1239, 1160, 1134, 1105, 700 cm-1; 
GC-MS (EI) m/z (M+) calcd for C16H21F3O: 286, found: 286. 
 
 
F3C Ph
OO
 
2-(5-Phenyl-3-(trifluoromethyl)pentyl)-1,3-dioxolane (Table 4, Entry 5).  The title 
compound was prepared according to the General Procedure with (3-bromo-4,4,4-
trifluorobutyl)benzene (214 mg, 0.80 mmol) and an alkylzinc bromide reagent prepared from 2-
(2-bromoethyl)-1,3-dioxolane.  Solvent system for chromatography: 10:1 → 6:1 hexane/ethyl 
acetate.  The title compound was isolated as a colorless oil. 
Run 1, 163 mg (71% yield); Run 2, 166 mg (72% yield). 
1H NMR (500 MHz, CDCl3) δ 7.33 – 7.28 (m, 2H), 7.23 – 7.17 (m, 3H), 4.85 (t, 1H, J = 4.2 Hz), 
4.01 – 3.93 (m, 2H), 3.90 – 3.82 (m, 2H), 2.78 – 2.66 (m, 2H), 2.21 – 2.09 (m, 1H), 1.96 (dddd, 1H, J 
= 14.3, 9.5, 6.8, 5.7 Hz), 1.83 – 1.70 (m, 4H), 1.69 – 1.62 (m, 1H); 
13C NMR (126 MHz, CDCl3) δ 141.1, 128.49, 128.48 (q, J = 280.5 Hz), 128.3, 126.1, 103.9, 64.95, 
64.92, 41.6 (q, J = 25.1 Hz), 32.8, 30.7, 29.5 (q, J = 2.3 Hz), 21.8 (q, J = 2.6 Hz); 
19F NMR (282 MHz, CDCl3) δ −69.9 (d, 3F, J = 9.4 Hz); 
FT-IR (film) 2955, 2881, 1454, 1396, 1263, 1145, 1116, 1031, 749, 700 cm-1; 
GC-MS (EI) m/z (M+) calcd for C15H19F3O2: 288, found: 288. 
 
 
F3C Ph
O
OEt
 
Ethyl 7-phenyl-5-(trifluoromethyl)heptanoate (Table 4, Entry 6).  The title compound was 
prepared according to the General Procedure with (3-bromo-4,4,4-trifluorobutyl)benzene (214 
mg, 0.80 mmol) and an alkylzinc bromide reagent prepared from ethyl 4-bromobutanoate.  
Solvent system for chromatography: 2:1 → 1:1.5 hexane/dichloromethane.  The title compound 
was isolated as a colorless oil. 
 S–15 
Run 1, 198 mg (82% yield); Run 2, 200 mg (83% yield). 
1H NMR (500 MHz, CDCl3) δ 7.32 – 7.28 (m, 2H), 7.23 – 7.18 (m, 3H), 4.15 (q, 2H, J = 7.1 Hz), 
2.74 – 2.68 (m, 2H), 2.30 (t, 2H, J = 7.0 Hz), 2.13 – 2.04 (m, 1H), 2.01 – 1.92 (m, 1H), 1.81 – 1.62 (m, 
4H), 1.56 – 1.49 (m, 1H), 1.27 (t, 3H, J = 7.1 Hz); 
13C NMR (126 MHz, CDCl3) δ 173.0, 141.1, 128.5, 128.4 (q, J = 280.4 Hz), 128.3, 126.2, 60.4, 41.7 
(q, J = 25.0 Hz), 34.1, 32.9, 29.4 (q, J = 2.4 Hz), 27.2 (q, J = 2.5 Hz), 22.0, 14.2; 
19F NMR (282 MHz, CDCl3) δ −69.9 (d, 3F, J = 9.4 Hz); 
FT-IR (film) 2942, 1734, 1262, 1184, 1147, 1114, 748, 700 cm-1; 
GC-MS (EI) m/z (M+) calcd for C16H21F3O2: 302, found: 302. 
 
 
PhF3C
Ph
 
(6-(Trifluoromethyl)oct-1-yne-1,8-diyl)dibenzene (Table 4, Entry 7).  The title compound 
was prepared according to the General Procedure with (3-bromo-4,4,4-trifluorobutyl)benzene 
(214 mg, 0.80 mmol) and an alkylzinc bromide reagent prepared from (5-bromopent-1-yn-1-
yl)benzene.  Solvent system for chromatography: 20:1 → 15:1 hexane/dichloromethane.  The 
title compound was isolated as a colorless oil. 
Run 1, 175 mg (66% yield); Run 2, 176 mg (67% yield). 
1H NMR (500 MHz, CDCl3) δ 7.43 – 7.39 (m, 2H), 7.33 – 7.27 (m, 5H), 7.24 – 7.18 (m, 3H), 2.81 
– 2.69 (m, 2H), 2.43 (t, 2H, J = 6.6 Hz), 2.21 – 2.08 (m, 1H), 2.00 (dddd, 1H, J = 14.2, 9.5, 6.8, 5.6 
Hz), 1.89 – 1.66 (m, 5H); 
13C NMR (126 MHz, CDCl3) δ 141.1, 131.5, 128.52 (q, J = 280.4 Hz), 128.51, 128.3, 128.2, 127.7, 
126.2, 123.7, 89.2, 81.3, 41.5 (q, J = 25.0 Hz), 32.9, 29.5 (q, J = 2.4 Hz), 26.9 (q, J = 2.4 Hz), 25.7, 19.4; 
19F NMR (282 MHz, CDCl3) δ −69.8 (d, 3F, J = 9.4 Hz); 
FT-IR (film) 2951, 1490, 1262, 1146, 1114, 756, 692 cm-1; 
GC-MS (EI) m/z (M+) calcd for C21H21F3: 330, found: 330. 
 
 
F3C Ph
CN
 
7-Phenyl-5-(trifluoromethyl)heptanenitrile (Table 4, Entry 8).  The title compound was 
prepared according to the General Procedure with (3-bromo-4,4,4-trifluorobutyl)benzene (214 
mg, 0.80 mmol) and an alkylzinc bromide reagent prepared from 4-bromobutanenitrile.  
Solvent system for chromatography: 10:1 → 4:1 hexane/ethyl acetate.  The title compound was 
isolated as a colorless oil. 
Run 1, 170 mg (83% yield); Run 2, 170 mg (83% yield). 
This compound was also prepared on a 6.00 mmol scale, using (3-bromo-4,4,4-
trifluorobutyl)benzene (1.60 g, 6.00 mmol) and an alkylzinc bromide reagent prepared from 4-
bromobutanenitrile (0.50 M; 14.4 mL, 7.20 mmol; 1.20 equiv).  Following the General Procedure 
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using 5.0% NiCl2⋅glyme (65.9 mg, 0.300 mmol) and 5.5% ligand 1 (99.5 mg, 0.330 mmol), the title 
compound was isolated in 80% yield (1.22 g). 
1H  NMR  (500  MHz,  CDCl3)  δ  7.34  –  7.30  (m,  2H),  7.25  –  7.18  (m,  3H),  2.79  –  2.68  (m,  2H),  2.32  
(t,  2H,  J  =  6.8  Hz),  2.15  –  2.06  (m,  1H),  2.02  (dddd,  1H,  J  =  14.5,  8.9,  6.9,  5.6  Hz),  1.82  –  1.62  (m,  
5H);  
13C  NMR  (126  MHz,  CDCl3)  δ  140.6,  128.6,  128.3,  128.1  (q,  J  =  280.3  Hz),  126.3,  119.0,  41.2  (q,  J  
=  25.3  Hz),  32.8,  29.4  (q,  J  =  2.4  Hz),  26.9  (q,  J  =  2.5  Hz),  22.6,  17.2;  
19F  NMR  (282  MHz,  CDCl3)  δ  −69.7  (d,  3F,  J  =  9.1  Hz);  
FT-­‐‑IR  (film)  3028,  2946,  2877,  2247,  1497,  1462,  1455,  1396,  1263,  1195,  1149,  1115,  1031,  751,  
701  cm-­‐‑1;  
GC-­‐‑MS  (EI)  m/z  (M+)  calcd  for  C14H16F3N:  255,  found:  255.  
  
  
F3C Ph
P
OEt
O
OEt
 
Diethyl (6-phenyl-4-(trifluoromethyl)hexyl)phosphonate (Table 4, Entry 9).  The title 
compound was prepared according to the General Procedure with (3-bromo-4,4,4-
trifluorobutyl)benzene (214 mg, 0.80 mmol) and an alkylzinc bromide reagent prepared from 
diethyl (3-bromopropyl)phosphonate.  Solvent system for chromatography: 4:1 → 1:3 
hexane/ethyl acetate.  The title compound was isolated as a colorless oil. 
Run 1, 258 mg (88% yield); Run 2, 260 mg (89% yield). 
1H NMR (500 MHz, CDCl3) δ 7.31 – 7.26 (m, 2H), 7.22 – 7.15 (m, 3H), 4.15 – 4.02 (m, 4H), 2.70 
(t, 2H, J = 8.1 Hz), 2.10 – 2.02 (m, 1H), 1.94 (dddd, 1H, J = 14.4, 8.7, 7.3, 5.8 Hz), 1.78 – 1.52 (m, 
7H), 1.31 (t, 6H, J = 7.1 Hz); 
13C NMR (126 MHz, CDCl3) δ 140.9, 128.5, 128.34 (q, J = 280.3 Hz), 128.28, 126.2, 61.5 (d, J = 
6.5 Hz), 41.6 (q, J = 25.4 Hz), 32.9, 29.4 (d, J = 2.3 Hz), 28.6 (dd, J = 16.7, 2.4 Hz), 25.6 (d, J = 141.8 
Hz), 19.9 (d, J = 4.8 Hz), 16.4 (d, J = 5.9 Hz); 
19F NMR (282 MHz, CDCl3) δ −69.8 (d, 3F, J = 9.3 Hz); 
31P NMR (121 MHz, CDCl3) δ 31.3; 
FT-IR (film) 2981, 2940, 1257, 1161, 1107, 1058, 1030, 960, 701 cm-1; 
GC-MS (EI) m/z (M+) calcd for C17H26F3O3P: 366, found: 366. 
 
 
F3C
OPh
n-Bu  
((4-(Trifluoromethyl)dodecyl)oxy)benzene (Table 5, Entry 1).  The title compound was 
prepared according to the General Procedure with 2-bromo-1,1,1-trifluorodecane (220 mg, 0.80 
mmol) and an alkylzinc bromide reagent prepared from (3-bromopropoxy)benzene.  Solvent 
system for chromatography: hexane → 10:1 hexane/dichloromethane.  The title compound 
was isolated as a colorless oil. 
Run 1, 225 mg (85% yield); Run 2, 230 mg (87% yield). 
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1H NMR (500 MHz, CDCl3) δ 7.32 – 7.26 (m, 2H), 6.97 – 6.93 (m, 1H), 6.92 – 6.88 (m, 2H), 3.97 
(t, 2H, J = 6.1 Hz), 2.10 (dddd, 1H, J = 15.7. 9.6, 6.4, 3.6 Hz), 1.94 – 1.84 (m, 2H), 1.83 – 1.73 (m, 
1H), 1.71 – 1.59 (m, 2H), 1.50 – 1.23 (m, 13H), 0.90 (t, 3H, J = 6.9 Hz); 
13C NMR (126 MHz, CDCl3) δ 158.9, 129.4, 128.6 (q, J = 280.4 Hz), 120.7, 114.4, 67.4, 42.3 (q, J = 
24.8 Hz), 31.8, 29.7, 29.4, 29.2, 27.8 (q, J = 2.4 Hz), 26.8, 26.6, 24.5 (q, J = 2.3 Hz), 22.7, 14.1; 
19F NMR (282 MHz, CDCl3) δ −70.1 (d, 3F, J = 9.5 Hz); 
FT-IR (film) 2927, 2856, 1601, 1498, 1245, 1160, 1133, 753, 691 cm-1; 
GC-MS (EI) m/z (M+) calcd for C19H29F3O: 330, found: 330. 
 
 
BrF3C
OPh
 
((12-Bromo-4-(trifluoromethyl)dodecyl)oxy)benzene (Table 5, Entry 2).  The title 
compound was prepared according to the General Procedure with 2,10-dibromo-1,1,1-
trifluorodecane (283 mg, 0.80 mmol) and an alkylzinc bromide reagent prepared from (3-
bromopropoxy)benzene.  Solvent system for chromatography: 10:1 → 6:1 
hexane/dichloromethane.  The title compound was isolated as a colorless oil. 
Run 1, 259 mg (79% yield); Run 2, 260 mg (79% yield). 
1H NMR (500 MHz, CDCl3) δ 7.32 – 7.27 (m, 2H), 6.97 – 6.93 (m, 1H), 6.92 – 6.88 (m, 2H), 3.97 
(t, 2H, J = 6.1 Hz), 3.41 (t, 2H, J = 6.8 Hz), 2.11 (ddtd, 1H, J = 15.6, 9.6, 5.9, 3.4 Hz), 1.92 – 1.73 (m, 
5H), 1.71 – 1.59 (m, 2H), 1.51 – 1.25 (m, 11H); 
13C NMR (126 MHz, CDCl3) δ 158.8, 129.4, 128.6 (q, J = 280.5 Hz), 120.7, 114.4, 67.3, 42.3 (q, J = 
24.8 Hz), 34.0, 32.8, 29.5, 29.2, 28.7, 28.1, 27.8 (q, J = 2.5 Hz), 26.7, 26.6, 24.4 (q, J = 2.5 Hz); 
19F NMR (282 MHz, CDCl3) δ −70.1 (d, 3F, J = 9.5 Hz); 
FT-IR (film) 2931, 2856, 1601, 1498, 1245, 1162, 1121, 754, 691 cm-1; 
GC-MS (EI) m/z (M+) calcd for C19H2879BrF3O: 408, found: 408, 410 (M++2). 
 
 
OTsF3C
OPh
 
9-Phenoxy-6-(trifluoromethyl)nonyl 4-methylbenzenesulfonate (Table 5, Entry 3).  The 
title compound was prepared according to the General Procedure with 6-bromo-7,7,7-
trifluoroheptyl 4-methylbenzenesulfonate (322 mg, 0.80 mmol) and an alkylzinc bromide 
reagent prepared from (3-bromopropoxy)benzene.  Solvent system for chromatography: 10:1 
hexane/ethyl acetate.  The title compound was isolated as a colorless oil. 
Run 1, 275 mg (75% yield); Run 2, 278 mg (76% yield). 
1H NMR (500 MHz, CDCl3) δ 7.81 – 7.76 (m, 2H), 7.36 – 7.32 (m, 2H), 7.31 – 7.25 (m, 2H), 6.96 
– 6.92 (m, 1H), 6.91 – 6.86 (m, 2H), 4.03 – 3.92 (m, 4H), 2.44 (s, 3H), 2.15 – 2.00 (m, 1H), 1.90 – 1.80 
(m, 2H), 1.79 – 1.71 (m, 1H), 1.69 – 1.53 (m, 4H), 1.46 – 1.25 (m, 5H); 
13C NMR (126 MHz, CDCl3) δ 158.8, 144.7, 133.1, 129.8, 129.4, 128.4 (q, J = 281.0 Hz), 127.8, 
120.7, 114.4, 70.3, 67.2, 42.2 (q, J = 24.8 Hz), 28.6, 27.6 (d, J = 2.7 Hz), 26.5, 26.1, 25.5, 24.4 (d, J = 
2.7 Hz), 21.6; 
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19F NMR (282 MHz, CDCl3) δ −70.0 (d, 3F, J = 9.5 Hz); 
FT-IR (film) 2946, 1600, 1498, 1360, 1246, 1189, 1177, 1157, 955, 815, 756, 664 cm-1; 
LC-MS (ESI) m/z (M+H+) calcd for C23H30F3O4S: 459, found: 459. 
 
 
OTBDPSF3C
CN
 
10-((tert-Butyldiphenylsilyl)oxy)-5-(trifluoromethyl)decanenitrile (Table 5, Entry 4).  The 
title compound was prepared according to the General Procedure with ((6-bromo-7,7,7-
trifluoroheptyl)oxy)(tert-butyl)diphenylsilane (390 mg, 0.80 mmol) and an alkylzinc bromide 
reagent prepared from 4-bromobutanenitrile.  Solvent system for chromatography: 10:1 → 8:1 
hexane/ethyl acetate.  The title compound was isolated as a colorless oil. 
Run 1, 268 mg (70% yield); Run 2, 281 mg (74% yield). 
1H NMR (500 MHz, CDCl3) δ 7.70 – 7.66 (m, 4H), 7.46 – 7.37 (m, 6H), 3.68 (t, 2H, J = 6.3 Hz), 
2.38 – 2.33 (m, 2H), 2.08 – 2.01 (m, 1H), 1.83 – 1.68 (m, 3H), 1.68 – 1.54 (m, 4H), 1.44 – 1.33 (m, 
5H), 1.06 (s, 9H); 
13C NMR (126 MHz, CDCl3) δ 135.5, 134.0, 129.5, 128.2 (q, J = 280.3 Hz), 127.6, 119.0, 63.7, 42.1 
(q, J = 25.2 Hz), 32.2, 27.7 (q, J = 2.4 Hz), 27.1 (q, J = 2.4 Hz), 26.8, 26.5, 25.8, 22.8, 19.2, 17.3; 
19F NMR (282 MHz, CDCl3) δ −69.9 (d, 3F, J = 9.3 Hz); 
FT-IR (film) 2933, 2858, 2247, 1428, 1258, 1153, 1112, 703 cm-1; 
GC-MS (EI) m/z (M+−C4H9) calcd for C23H27F3NOSi: 418, found: 418. 
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O
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9-Phenoxy-6-(trifluoromethyl)nonyl furan-2-carboxylate (Table 5, Entry 5).  The title 
compound was prepared according to the General Procedure with 6-bromo-7,7,7-trifluoroheptyl 
furan-2-carboxylate (274 mg, 0.80 mmol) and an alkylzinc bromide reagent prepared from (3-
bromopropoxy)benzene.  Solvent system for chromatography: 20:1 hexane/ethyl acetate.  The 
title compound was isolated as a colorless oil. 
Run 1, 267 mg (84% yield); Run 2, 258 mg (81% yield). 
1H NMR (500 MHz, CD3COCD3) δ 7.80 (dd, 1H, J = 1.8, 0.8 Hz), 7.30 – 7.25 (m, 2H), 7.22 (dd, 
1H, J = 3.5, 0.9 Hz), 6.96 – 6.89 (m, 3H), 6.63 (dd, 1H, J = 3.5, 1.8 Hz), 4.27 (t, 2H, J = 6.6 Hz), 4.03 
(t, 2H, J = 6.1 Hz), 2.38 – 2.25 (m, 1H), 1.94 – 1.64 (m, 7H), 1.60 – 1.43 (m, 5H); 
13C NMR (126 MHz, CD3COCD3) δ 160.1, 159.1, 147.9, 146.0, 130.4, 130.1 (q, J = 279.8 Hz), 
121.5, 118.7, 115.5, 112.9, 68.2, 65.4, 43.0 (q, J = 24.6 Hz), 29.4, 28.6 (q, J = 2.5 Hz), 27.4, 27.3, 26.9, 
25.3 (q, J = 2.7 Hz); 
19F  NMR  (282  MHz,  CD3COCD3)  δ  −70.6  (d,  3F,  J  =  9.9  Hz);  
FT-IR (film) 2948, 2871, 1722, 1601, 1586, 1498, 1475, 1398, 1297, 1246, 1180, 1120, 1078, 755, 
692 cm-1; 
GC-MS (EI) m/z (M+) calcd for C21H25F3O4: 398, found: 398. 
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10-(4-Iodophenoxy)-5-(trifluoromethyl)decanenitrile (Table 5, Entry 6).  The title 
compound was prepared according to the General Procedure with 1-((6-bromo-7,7,7-
trifluoroheptyl)oxy)-4-iodobenzene (361 mg, 0.80 mmol) and an alkylzinc bromide reagent 
prepared from 4-bromobutanenitrile.  Solvent system for chromatography: 10:1 → 4:1 
hexane/ethyl acetate.  The title compound was isolated as a white solid. 
Run 1, 283 mg (81% yield); Run 2, 285 mg (81% yield). 
1H NMR (500 MHz, CDCl3) δ 7.56 – 7.52 (m, 2H), 6.69 – 6.64 (m, 2H), 3.92 (t, 2H, J = 6.3 Hz), 
2.40 – 2.35 (m, 2H), 2.14 – 2.02 (m, 1H), 1.84 – 1.59 (m, 7H), 1.51 – 1.41 (m, 5H); 
13C NMR (126 MHz, CDCl3) δ 158.8, 138.1, 128.1 (q, J = 280.3 Hz), 119.0, 116.9, 82.5, 67.7, 42.1 
(q, J = 25.3 Hz), 28.9, 27.7 (q, J = 2.4 Hz), 27.1 (q, J = 2.4 Hz), 26.5, 26.1, 22.8, 17.4; 
19F NMR (282 MHz, CDCl3) δ −69.9 (d, 3F, J = 9.3 Hz); 
FT-IR (film) 2943, 2246, 1586, 1487, 1244, 1174, 1153, 1125, 821 cm-1; 
GC-MS (EI) m/z (M+) calcd for C17H21F3INO: 439, found: 439. 
 
 
F3C
OPh
N
Boc
 
tert-Butyl 4-(5-phenoxy-2-(trifluoromethyl)pentyl)piperidine-1-carboxylate (Table 5, Entry 
7).  The title compound was prepared according to the General Procedure with tert-butyl 4-(2-
bromo-3,3,3-trifluoropropyl)piperidine-1-carboxylate (288 mg, 0.80 mmol) and an alkylzinc 
bromide reagent prepared from (3-bromopropoxy)benzene.  Solvent system for 
chromatography: 25:1 → 15:1 hexane/ethyl acetate.  The title compound was isolated as a 
colorless oil. 
Run 1, 267 mg (80% yield); Run 2, 265 mg (80% yield). 
1H NMR (500 MHz, CDCl3) δ 7.31 – 7.26 (m, 2H), 6.97 – 6.93 (m, 1H), 6.90 – 6.86 (m, 2H), 4.16 
– 4.02 (m, 2H), 3.99 – 3.95 (m, 2H), 2.73 – 2.57 (m, 2H), 2.27 – 2.16 (m, 1H), 1.94 – 1.75 (m, 3H), 
1.71 – 1.61 (m, 3H), 1.60 – 1.50 (m, 2H), 1.46 (s, 9H), 1.38 – 1.30 (m, 1H), 1.15 – 1.01 (m, 2H); 
13C NMR (126 MHz, CDCl3) δ 158.7, 154.7, 129.5, 128.5 (q, J = 280.0 Hz), 120.8, 114.4, 79.3, 
67.1, 39.2 (q, J = 25.1 Hz), 34.9, 33.4, 32.3, 31.9, 28.4, 26.4, 25.1 (d, J = 2.5 Hz); 
19F NMR (282 MHz, CDCl3) δ −70.4 (d, 3F, J = 9.3 Hz); 
FT-IR (film) 2973, 2933, 2870, 1692, 1498, 1424, 1366, 1246, 1171, 1138, 755, 692 cm-1; 
GC-MS (EI) m/z (M+−Boc) calcd for C17H23F3NO: 314, found: 314. 
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1-(4-((9-Phenoxy-6-(trifluoromethyl)nonyl)oxy)phenyl)ethan-1-one (Table 5, Entry 8).  
The title compound was prepared according to the General Procedure with 1-(4-((6-bromo-7,7,7-
trifluoroheptyl)oxy)phenyl)ethan-1-one (294 mg, 0.80 mmol) and an alkylzinc bromide reagent 
prepared from (3-bromopropoxy)benzene.  Solvent system for chromatography: 10:1 → 4:1 
hexane/ethyl acetate.  The title compound was isolated as a yellow oil. 
Run 1, 291 mg (86% yield); Run 2, 287 mg (85% yield). 
1H NMR (500 MHz, CDCl3) δ 7.95 – 7.90 (m, 2H), 7.31 – 7.25 (m, 2H), 6.98 – 6.86 (m, 5H), 4.01 
(t, 2H, J = 6.4 Hz), 3.96 (t, 2H, J = 6.0 Hz), 2.55 (s, 3H), 2.13 (dddd, 1H, J = 14.7, 8.8, 5.8, 3.1 Hz), 
1.93 – 1.74 (m, 5H), 1.72 – 1.62 (m, 2H), 1.57 – 1.42 (m, 5H); 
13C NMR (126 MHz, CDCl3) δ 196.7, 163.0, 158.8, 130.6, 130.2, 129.4, 128.5 (q, J = 280.4 Hz), 
120.7, 114.4, 114.1, 67.9, 67.3, 42.2 (q, J = 25.0 Hz), 28.9, 27.7 (d, J = 2.3 Hz), 26.6, 26.5, 26.3, 26.1, 
24.5 (d, J = 2.5 Hz); 
19F NMR (282 MHz, CDCl3) δ −70.0 (d, 3F, J = 9.5 Hz); 
FT-IR (film) 2945, 1676, 1601, 1254, 1172, 1158, 1124, 834, 755, 692 cm-1; 
LC-MS (ESI) m/z (M+H+) calcd for C24H30F3O3: 423, found: 423. 
 
 
F3CF2C Ph
OPh
 
((5,5,6,6,6-Pentafluoro-4-phenethylhexyl)oxy)benzene (eq 5).  The title compound was 
prepared according to the General Procedure with (4,4,5,5,5-pentafluoro-3-iodopentyl)benzene 
(291 mg, 0.80 mmol) and an alkylzinc bromide reagent prepared from (3-
bromopropoxy)benzene.  Solvent system for chromatography: 10:1 → 3:1 
hexane/dichloromethane.  The title compoundwas isolated as a colorless oil. 
Run 1, 186 mg (62% yield); Run 2, 183 mg (61% yield). 
For the characterization data, see Table 2, Entry 1 (above). 
 
 
Competition Experiments (Table 6).  In a nitrogen-filled glovebox, NiCl2⋅glyme (2.2 mg, 
0.010 mmol), ligand 1 (3.3 mg, 0.011 mmol), and NaBr (10.3 mg, 0.10 mmol) were added to an 
oven-dried 4-mL vial equipped with a stir bar.  DMA (0.25 mL) was added to the 4-mL vial, 
and the vial was closed with a PTFE septum cap.  The mixture was vigorously stirred at r.t. for 
25 min.  Then, a solution in DMA of each of the two alkyl electrophiles (0.10 mmol in 0.25 mL 
of DMA) was added in turn to the 4-mL vial.  The combined mixture was allowed to stir at r.t. 
for 1 min.  Next, the solution of the alkylzinc reagent (0.50 M; 0.24 mL, 0.12 mmol; 1.2 equiv) 
was added in one portion.  The reaction mixture was stirred vigorously at r.t. for 10 min, and 
then the reaction was quenched with MeOH (0.2 mL).  A solution of PhCF3 (0.20 M; 0.50 mL, 
0.10 mmol; 1.0 equiv) in CDCl3 was added to the vial as an internal standard, and the reaction 
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mixture was analyzed by 19F NMR spectroscopy.  When (3-bromobutyl)benzene was used as 
the electrophile, n-tetradecane (26 µL) was added to the vial as another internal standard, and 
the reaction mixture was also analyzed by GC. 
 
 
Study of the effect of TEMPO: 
Eq 6, without TEMPO: In a nitrogen-filled glovebox, NiCl2⋅glyme (2.2 mg, 0.010 mmol), 
ligand 1 (3.3 mg, 0.011 mmol), and NaBr (10.3 mg, 0.10 mmol) were added to an oven-dried 4-
mL vial equipped with a stir bar.  DMA (0.25 mL) was added to the 4-mL vial, and the vial was 
closed with a PTFE septum cap.  The mixture was stirred vigorously at r.t. for 25 min.  Then, a 
solution of the alkyl electrophile in DMA (0.10 mmol in 0.25 mL of DMA) was added to this 
solution.  The resulting solution was allowed to stir at r.t. for 1 min.  Next, a solution of the 
alkylzinc reagent (0.50 M; 0.24 mL, 0.12 mmol; 1.2 equiv) was added in one portion.  The 
mixture was stirred vigorously at r.t. for 2 min, and then the reaction was quenched with MeOH 
(0.2 mL).  A solution of PhCF3 (0.20 M; 0.50 mL, 0.10 mmol; 1.0 equiv) in CDCl3 was added to 
the vial as an internal standard, and the reaction mixture was analyzed by 19F NMR 
spectroscopy. 
Eq 6, with TEMPO: In a nitrogen-filled glovebox, (3-bromo-4,4,4-trifluorobutyl)benzene 
(26.7 mg, 0.10 mmol) and NaBr (10.3 mg, 0.10 mmol) were added to an oven-dried 4-mL vial 
equipped with a stir bar.  DMA (0.25 mL) was added to this vial, and then a solution of 
TEMPO in DMA (0.15 M; 0.10 mL, 0.015 mmol; 0.15 equiv) and a solution of the alkylzinc 
reagent (0.50 M; 0.24 mL, 0.12 mmol; 1.2 equiv). 
In a nitrogen-filled glove box, NiCl2⋅glyme (6.6 mg, 0.030 mmol) and ligand 1 (9.9 mg, 0.033 
mmol) were added to a second oven-dried 4-mL vial equipped with a stir bar.  DMA (0.75 mL) 
was added to this vial, and the vial was closed with a PTFE septum cap.  The mixture was 
vigorously stirred at r.t. for 25 min.  Next, 0.25 mL of this catalyst stock solution was added to 
the 4-mL reaction vial in one portion.  The resulting mixture was stirred vigorously at r.t. for 2 
min, and then the reaction was quenched with MeOH (0.2 mL).  A solution of PhCF3 (0.20 M; 
0.50 mL, 0.10 mmol; 1.0 equiv) in CDCl3 was added to the vial as an internal standard, and the 
reaction mixture was analyzed by 19F NMR spectroscopy. 
Eq 7: In a nitrogen-filled glovebox, (3-bromo-4,4,4-trifluorobutyl)benzene (26.7 mg, 0.10 
mmol) and NaBr (10.3 mg, 0.10 mmol) were added to an oven-dried 4-mL vial equipped with a 
stir bar.  DMA (0.25 mL) was added to this vial, and then a solution of TEMPO in DMA (0.15 
M; 0.10 mL, 0.015 mmol; 0.15 equiv) and a solution of the alkylzinc reagent (0.50 M; 0.24 mL, 
0.12 mmol; 1.2 equiv).. 
In a nitrogen-filled glove box, NiCl2⋅glyme (6.6 mg, 0.030 mmol) and ligand 1 (9.9 mg, 0.033 
mmol) were added to a second oven-dried 4-mL vial equipped with a stir bar.  DMA (0.75 mL) 
was added to this vial, and the vial was closed with a PTFE septum cap.  The mixture was 
vigorously stirred at r.t. for 25 min.  Next, 0.25 mL of this catalyst stock solution was added to 
the 4-mL reaction vial in one portion.  The resulting mixture was stirred vigorously at r.t. for 15 
min, and then the reaction was quenched with MeOH (0.2 mL).  A solution of PhCF3 (0.20 M; 
0.50 mL, 0.10 mmol; 1.0 equiv) in CDCl3 was added to the vial as an internal standard, and the 
reaction mixture was analyzed by 19F NMR spectroscopy. 
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2,2,6,6-Tetramethyl-1-((1,1,1-trifluoro-4-phenylbutan-2-yl)oxy)piperidine (eq 7; 
preparation of an authentic sample).  The title compound was prepared according to the 
General Procedure with (3-bromo-4,4,4-trifluorobutyl)benzene (267 mg, 1.00 mmol) and an 
alkylzinc bromide reagent prepared from 1-bromononane, in the presence of TEMPO (94 mg, 
0.40 mmol), NiCl2⋅glyme (88 mg, 0.40 mmol), and ligand 1 (133 mg, 0.44 mmol).  Solvent 
system for chromatography: hexane → 7:1 hexane/dichloromethane.  The title compound was 
isolated as a colorless oil (98 mg, 71% yield). 
1H  NMR  (500  MHz,  CDCl3)  δ  7.33  –  7.28  (m,  2H),  7.24  –  7.19  (m,  3H),  4.32  –  4.24  (m,  1H),  2.84  
(ddd,  1H,  J  =  16.2,  11.4,  5.0  Hz),  2.75  (ddd,  1H,  J  =  14.0,  10.6,  6.5  Hz),  2.49  –  2.40  (m,  1H),  2.07  –  
1.97  (m,  1H),  1.67  –  1.40  (m,  5H),  1.37  –  1.28  (m,  1H),  1.21  –  1.06  (m,  12H);  
13C  NMR  (126  MHz,  CDCl3)  δ  141.3,  128.44,  128.36,  126.0,  125.3  (q,  J  =  283.3  Hz),  79.5  (q,  J  =  
27.5  Hz),  61.1,  60.2,  40.5,  33.9,  33.4,  31.6  (d,  J  =  1.7  Hz),  29.8  (d,  J  =  1.3  Hz),  20.3,  17.1;  
19F  NMR  (282  MHz,  CDCl3)  δ  −73.3  (d,  3F,  J  =  6.9  Hz);  
FT-­‐‑IR  (film)  2976,  2933,  2873,  1457,  1378,  1363,  1264,  1189,  1159,  1132,  1090,  748,  698  cm-­‐‑1;  
HRMS  (ESI)  m/z  (M+H+)  calcd  for  C19H29F3NO:  344.2201,  found:  344.2194.  
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